loading page

SARS-CoV-2 breakthrough infection and death in COVID-19 vaccines recipients in North of Iran in 2021
  • +9
  • Rouhollah Shabestan,
  • Bahman Amani,
  • Behnam Amani,
  • Arash Akbarzadeh,
  • Maryam Zamani,
  • Mohammad Saeidi ,
  • Seyede Roghayyeh Mirshojaie,
  • Narjes Abdolmohammadi,
  • Mohammad Reza Parsaie,
  • Korosh Rajabkhah,
  • Vida Kardanmoghadam,
  • Seyede Samaneh Momeni
Rouhollah Shabestan
Tehran University of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Bahman Amani
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences
Author Profile
Behnam Amani
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences
Author Profile
Arash Akbarzadeh
Department of Biostatistics and Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Author Profile
Maryam Zamani
Hamadan University of Medical Sciences
Author Profile
Mohammad Saeidi
Mazandaran University of Medical Sciences
Author Profile
Seyede Roghayyeh Mirshojaie
Islamic Azad University
Author Profile
Narjes Abdolmohammadi
Tehran University of Medical Sciences
Author Profile
Mohammad Reza Parsaie
. Health Deputy, Mazandaran University of Medical Sciences, Sari, Iran
Author Profile
Korosh Rajabkhah
Iran Ministry of Health and Medical Education
Author Profile
Vida Kardanmoghadam
Tehran University of Medical Sciences
Author Profile
Seyede Samaneh Momeni
Islamic Azad University Sari Branch
Author Profile

Abstract

Aim: This study aimed to assess the cases of SARS-CoV-2 breakthrough infection and death among AZD1222, Sinopharm, Sputink V, Soberana, and COVAXIN vaccines receivers in Mazandaran. Methods: This retrospective cohort study was involving 320260 cases who received fully vaccinated (two doses) with five types of COVID-19 vaccine (ChAdOx1 nCoV-19, Sinopharm, Sputink V, Soberana, and COVAXIN) between February 2021 to August 2021 in the Mazandaran province. The outcomes of interest were SARS-CoV-2 breakthrough infection and death due to COVID-19 after vaccination. Data were analyzed using R software. Results: Among 320260 COVID-19 vaccine recipients, 712 (0.22%) cases of SARS-CoV-2 breakthrough infections were identified and 94 (0.029%) hospitalized patients died from COVID-19. The cases of SARS-CoV-2 breakthrough infections were in Sinopharm (0.26%), ChAdOx1 nCoV-19 (0.09%), Sputnik (0.21%) Soberana (0.01%) and Covaxin (0.38%), respectively. The cases of death in vaccine recipients in Sinopharm, AZD1222, Sputnik, Soberana, and Covaxin were 81, 11, 1, 1, and 0 cases, respectively. A significant difference was observed between COVID-19 vaccines in terms of death (P<0.05). Conclusion: Based on the findings, the most cases of SARS-CoV-2 breakthrough infection and death were observed in Sinopharm vaccine receivers.